Retatrutide
Retatrutide 5mg lyophilised powder — the starting dosage for clinical titration protocols. Produced to pharmaceutical-grade standards for reconstitution in clinical weight management settings.
Request a Quote
Pricing available for qualified medical professionals, clinics, and distributors.
Enquire NowDownload MonographView FAQMechanism of Action
Retatrutide is a triple agonist peptide targeting three receptors simultaneously: GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. GIP and GLP-1 receptor activation reduces appetite and promotes satiety via hypothalamic signalling, while glucagon receptor activation increases energy expenditure and promotes hepatic lipid oxidation. This triple mechanism has demonstrated the most substantial weight reduction of any pharmaceutical agent in clinical trials to date.
Read the researchClinical Benefits
- Triple receptor agonist (GIP/GLP-1/Glucagon)
- Supports clinical weight management protocols
- Pharmaceutical-grade lyophilised formulation
- Precise dosing for titration schedules
Specifications
Storage & Handling
- Store lyophilised vials at 2–8°C
- Protect from light
- Reconstituted solution: 2–8°C, use per clinical protocol
For professional medical use only. Not for retail sale to the general public. Pricing available on request for qualified medical institutions and distributors.